Programme Day 1

09.00 - 10.00

BSHT PhD/Early Post-doc Session
Hall: Lomond

Moderator: Jim Crawley (United Kingdom)

  • 09.00 – 09.20: Fibrin films and where to find them, Fraser Macrae, University of Leeds
  • 09.20 – 09.40: Factor XII driven coagulation, Lewis Hardy, University of Leeds
  • 09.40 – 10.00: Allosteric activation of ADAMTS13Tassos PetriImperial College London

Platelet Society Session/ Early Post-doc Session
Hall: Alsh

Moderator: Khalid Naseem (United Kingdom)

  • 09.00 – 09.15: Dihomo – Y linolenic acid enhances aspirin-mediated inhibition and alters the proteomic releasate profile in platelets, Laura Menke, Queen Mary University London
  • 09.15 – 09.30: The differential requirement of the Btk kinase domain downstream of ITAM and hemITAM signalling, Sophie Nock, University of Reading
  • 09.30 – 09.45: Multicolour flow cytometry reveals platelet subpopulations that are regulated by prostacyclin, Matt Hindle, University of Leeds
  • 09.45 – 10.00: Platelet ageing causes changes in key metabolic and structural proteins, Harriet Allan, Queen Mary University London

10.00 - 10.30

Coffee Break & Poster Viewing

10.30 - 12.15

BSHT Session
Hall: Lomond 

Moderator: Jim Crawley (United Kingdom)

  • 10.30 – 11.00: Novel prothrombin variant causing inherited thrombophilia, Vincent Muczynski, University College London
  • 11.00 – 11.30: VWF, platelets and neutrophils – novel roles of GPIba, aIIbb3 and SLC44A2, Isabelle Salles-Crawley, Imperial College London
  • 11.30 – 12.00: Thrombotic Thrombocytopenic Purpura (TTP) – from pathogenesis of disease to treatment, Mari Thomas, University College London
  • 12.00 – 12.15: Discussion

The Platelet Society Session
Hall: Alsh

Moderator: Khalid Naseem (United Kingdom)

  • 10.30 – 11.00: Repurposing anti-cancer drugs, could Pim kinase inhibitors be the new aspirin? Amanda Unsworth, Manchester Metropolitan University
  • 11.00 – 11.30: Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability, Jo MitchellUniversity of Reading
  • 11.30 – 12.00: Recombinant Von Willebrand Factor (Vonvendi) mediates acute reversal of platelet dysfunction induced by antiplatelet agents, Alex Bye, University of Reading
  • 12.00 – 12.15: Discussion

BSH Session
Hall: Boisdale

Moderator: Cheng-Hock Toh (United Kingdom)

  • 10.30 – 11.00: Refractory thrombotic thrombocytopenic purpura: Why and how I treat, Tina Dutt, Royal Liverpool University Hospital
  • 11.00- 11.30: Refractory immune thrombocytopenic purpura: Why and how I treat, Nichola Cooper, Imperial College London
  • 11.30 – 12.00: Recurrent thrombosis in anti-phospholipid syndrome: Why and how I treat, Hannah Cohen, University College London
  • 12.00 – 12.15: Discussion

12.15 - 13.15

Lunch Break



Special Symposium

(not part of main CME programme)

13.15 - 14.45

Venous Thrombosis: Risk
Oral Communications
Hall: Lomond 


Moderators: Isabelle Salles-Crawley (United Kingdom) and Carolina Touw (The Netherlands)

  • 13.15 – 13.30: The effect of thrombophilic risk factors on VTE risk in orthopaedic surgical patients: results of a large population-based case-control study, Carolina Touw, The Netherlands
  • 13.30 – 13.45: Plasma levels of a complement factor H related protein are associated with VTE, Maria Jesus Iglesias, Norway
  • 13.45 – 14.00: Thrombosis risk after switching oral contraceptive type, Deeksha Khialani, The Netherlands
  • 14.00 – 14.15: Impact of dietary intake of marine n-3 polyunsaturated fatty acids on surgery as a trigger for venous thromboembolism: results from a case-crossover study, Trond Isaksen, Norway
  • 14.15 – 14.30: Splanchnic vein thrombosis and antithrombin deficiency, María Eugenia De La Morena-Barrio, Spain
  • 14.30 – 14.45: Combined effect between genetic risk factors and pregnancy/postpartum period on the risk of venous thrombosis, Sara Arcudi, Italy

Bleeding Disorders and Therapy
Oral Communications
Hall: Alsh

Moderators: Guy Young (United States) and Samantha Gouw (The Netherlands)

  • 13.15 – 13.30: Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors, Guy Young, United States
  • 13.30 – 13.45: Functional investigation of a CD36 variant in patients with an inherited bleeding disorder, Ibrahim Almazni, United Kingdom
  • 13.45 – 14.00: Antithrombotic therapy with an anti-glycoprotein VI humanized Fab does not increase the risk of inflammation-associated bleeding in mice, Soumaya Jadoui, France
  • 14.00 – 14.15: Modulation of alternative splicing of the F5 gene using morpholino antisense oligonucleotides, Alice Todaro, The Netherlands
  • 14.15 – 14.30: Functional characterization of FV deficiency in Norway: Effects of F5 mutations on secretion, endoplasmic reticulum stress, apoptosis, and activated protein C sensitivity, Nina Iversen, Norway
  • 14.30 – 14.45: Evaluation of different therapeutic strategies to manage the rare coagulation defect due to enhanced protein C activity induced by the thrombomodulin c.1611C>Ap.Cys537Stop mutation, Gael Morrow, United Kingdom

Basic Clotting
Oral Communications
Hall: Boisdale



Moderators: Josefin Ahnström (United Kingdom) and Belén De La Morena-Barrio (Spain)

  • 13.15 – 13.30: Repetitive genomic sequences and their role in antithrombin deficiency, Belén De La Morena-Barrio, Spain
  • 13.30 – 13.45: Fine mapping of anti-spacer autoantibodies from immune-mediated thrombotic thrombocytopenic purpura patients using ADAMTS13/ADAMTS1 spacer hybrids, Leydi Carolina Velasquez Pereira, Belgium
  • 13.45 – 14.00: Partial rescue of naturally occurring active site factor X variants through decreased inhibition by tissue factor pathway inhibitor and antithrombin, Josefin Ahnström, United Kingdom
  • 14.00 – 14.15: Thrombosis and genetics: is p.Arg541Trp the future Breizh prothrombin? Alexandre Fauché, France
  • 14.15 – 14.30: Comparison of the procoagulant activity of extracellular vesicles obtained from cellular monolayers and spheroids, Araci Rondon, The Netherlands
  • 14.30 – 14.45: The critical role of tissue factor pathway inhibitor (TFPI) under flow and in vivo, Parvathy Sasikumar, United Kingdom

Platelets 1
Oral Communications
Hall: Carron



Moderators: Adela Constantinescu-Bercu (United Kingdom) and John Blackwood (United Kingdom)

  • 13.15 – 13.30: NOX1 inhibitors suppress collagen-stimulated platelet activation in vitro and endothelial damage-induced carotid occlusion in vivo with no effect on haemostasis, Giordano Pula, United Kingdom
  • 13.30 – 13.45: Critical role of platelets during lung fibrosis, Raphaël Martos, France
  • 13.45 – 14.00: Platelet integrin alphaIIbbeta3 and phosphatidylserine are vital in extracellular vesicle release from activated platelets, Alexandra Heinzmann, The Netherlands
  • 14.00 – 14.15: Deep Phenotyping of Platelet Sensitivity and Response Capacity, Joanne Dunster, United Kingdom
  • 14.15 – 14.30: Novel platelet-neutrophil interaction between activated αIIbβ3 and SLC44A2 mediates NETosis under flow, Adela Constantinescu-Bercu, United Kingdom
  • 14.30 – 14.45: Towards a quantitative ex vivo assessment of the innate immune system participation in thrombus formation, Daria Morozova, Russia

14.45 - 15.00

Coffee Break & Poster Viewing

15.00 - 16.00

Plenary Lecture

A History of Scottish Medicine

Gordon Lowe

United Kingdom

Hall: Lomond 

Moderator: Frits Rosendaal (The Netherlands)

16.00 - 16.30

Coffee Break & Poster Viewing

16.30 - 17.30

Science, Fast and Furious

Hall: Lomond 

Moderators: Tilman Hackeng (The Netherlands) and Sara Arcudi (Italy)

  • 16.30 – 16.45: Hypertensive complications of pregnancy and risk of venous thromboembolism: a population based cohort study in 2 million pregnant women, Luuk Scheres, The Netherlands
  • 16.45 – 17.00: In vitro and in vivo modulation of von Willebrand factor gene mutations with dominant-negative effect, Caterina Casari, France
  • 17.00 – 17.15: The Use of In Vitro Clot Lysis Assay For Predicting Outcomes and Safety In Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis, Zsuzsa Bagoly, Hungary
  • 17.15- 17.30: Identification of a low shear stress-specific anti-thrombotic pathway in the microvasculature orchestrated by the endothelial transcription factor ERG, Claire Peghaire, United Kingdom

17.30 - 18.00

Opening Ceremony

Hall: Lomond

18.00 - 19.00

Welcome Reception

After an entertaining Opening Ceremony, meet your peers and network with fellow congress delegates, enjoy a drink and some delicious bites. Welcome to Glasgow!